Your account is not claimed yet. You can sign up with ORCID to claim your account.

Koichiro Ohmura

ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 9

Top Venues

Modern rheumatology

Rheumatology international

Modern rheumatology case reports

Immunological medicine

Kyoto University Graduate School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Kyoto University Graduate School of Medicine Apr 1o 1994 - Mar 31o 1998

Japan

PHD

Publications

Daichi Umemoto, Shuji Sumitomo, Shohei Fujita, Hayato Shimizu, Hideki Oka, Maki Kanamori, Hiroaki Nishioka, Koichiro Ohmura
Four Cases of Dermatomyositis with Abnormally High Anti-MDA-5 Antibody Titers and not High Levels of Serum Ferritin. Modern rheumatology case reports (2022)
Yoichi Nakayama, Ryu Watanabe, Kosaku Murakami, Koichi Murata, Masao Tanaka, Hiromu Ito, Wataru Yamamoto, Kosuke Ebina, Kenichiro Hata, Yuri Hiramatsu, Masaki Katayama, Yonsu Son, Hideki Amuro, Kengo Akashi, Akira Onishi, Ryota Hara, Keiichi Yamamoto, Koichiro Ohmura, Shuichi Matsuda, Akio Morinobu, Motomu Hashimoto
Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study. Rheumatology international 42 (7) (2022)
Sze-Ming Law, Shuji Akizuki, Akio Morinobu, Koichiro Ohmura
A case of refractory systemic lupus erythematosus with monocytosis exhibiting somatic KRAS mutation. Inflammation and regeneration 42 (1) (2022)
Tomoya Nakajima, Ryu Watanabe, Motomu Hashimoto, Koichi Murata, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Wataru Yamamoto, Koji Kitagori, Shuji Akizuki, Ran Nakashima, Hajime Yoshifuji, Koichiro Ohmura, Shuichi Matsuda, Akio Morinobu
Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients. Rheumatology international (2021)
Ryu Watanabe, Motomu Hashimoto, Koichi Murata, Kosaku Murakami, Masao Tanaka, Koichiro Ohmura, Hiromu Ito, Shuichi Matsuda
Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunological medicine (2021)
Takeshi Iwasaki, Shuichiro Nakabo, Chikashi Terao, Kosaku Murakami, Ran Nakashima, Motomu Hashimoto, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Yasuo Miura, Kimiko Yurugi, Taira Maekawa, Myrthe A M van Delft, Leendert A Trouw, Takao Fujii, Tsuneyo Mimori, Koichiro Ohmura
Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. Arthritis research & therapy 22 (1) (2020)
Koichiro Ohmura
Which is the best SLE activity index for clinical trials? Modern rheumatology 31 (1) (2020)
Aki Nishioka, Shinichiro Tsunoda, Takeo Abe, Takahiro Yoshikawa, Miki Takata, Masayasu Kitano, Kiyoshi Matsui, Ran Nakashima, Yuji Hosono, Koichiro Ohmura, Tsuneyo Mimori, Hajime Sano
Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Modern rheumatology 29 (5) (2019)
Namiko Okabe, Koichiro Ohmura, Masaki Katayama, Shuji Akizuki, Nick Carpino, Kosaku Murakami, Ran Nakashima, Motomu Hashimoto, Yoshitaka Imura, Hajime Yoshifuji, Masao Tanaka, Tsuneyo Mimori
Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice. Modern rheumatology 28 (4) (2017)

Koichiro Ohmura.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Koichiro Ohmura